About Our Company

About Us

Teewinot Life Sciences is a global leader in the biosynthetic development and production of cannabinoids and their derivatives for consumer and pharmaceutical products. The Company is leveraging a unique integrated biocatalytic and chemical synthesis platform, that allows the production of an unprecedented range of cannabinoids and cannabinoid NCEs from bench to cGMP manufacturing.  This platform supports Teewinot’s drug discovery programs as well as industry partnerships for pharmaceutical and consumer product development. Teewinot is revolutionizing the synthetic cannabinoid space with its cost-effective, commercial scale approach to meet the global growing demand for cannabinoid-based products to address unmet health, wellness, and therapeutic needs.

Company Strategy
First To
MAKE
Diverse Portfolio At Scale Proprietary modular platform with current ability to produce cGMP THC, CBD, and to date 25 additional minor cannabinoids. In addition, Teewinot has generated a novel cannabinoid library as well as other novel analogs as new chemical entities.
FIRST TO
ANNOTATE
Exploring Endocannabinoid Physiology Leveraging cannabinoid expertise integrated with cutting edge approaches, TLS is diligently building a knowledge base to expand and define market opportunities for Teewinot’s cannabinoid assets.
FIRST TO
POSITION
Evidence-Based Product Development Through continued expansion of our cannabinoid biology and pharmacology knowledge combined with proprietary scalable manufacturing processes, TLS has a first-mover advantage for product development utilizing minor cannabinoids and novel analogs.
FIRST TO
MARKET
The Cannabinoid Partner of Choice Accessing consumer and pharmaceutical markets via strategic licensing, jointventures and partnership deals that range from consumer supply agreements to drug development.